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Meningiomas are common primary central nervous system tumors derived from the
meninges, with management most frequently entailing serial monitoring or a combination
of surgery and/or radiation therapy. Although often considered benign lesions,
meningiomas can not only be surgically inaccessible but also exhibit aggressive growth
and recurrence. In such cases, adjuvant radiation and systemic therapy may be required
for tumor control. In this review, we brieﬂy describe the current WHO grading scale for
meningioma and provide demonstrative cases of treatment-resistant meningiomas. We
also summarize frequently observed molecular abnormalities and their correlation with
intracranial location and recurrence rate. We then describe how genetic and epigenetic
features might supplement or even replace histopathologic features for improved
identiﬁcation of aggressive lesions. Finally, we describe the role of surgery,
radiotherapy, and ongoing systemic therapy as well as precision medicine clinical trials
for the treatment of recurrent meningioma.
Keywords: meningioma, CNS tumors, chemotherapy, radiation therapy, immunotherapy, skull base surgery

INTRODUCTION
Meningiomas are the most common primary central nervous system (CNS) tumor, constituting
more than 35% of adult brain tumors (1). At present, these tumors are classiﬁed by the World
Health Organization (WHO) into three grades: WHO grade 1 (benign, representing the majority of
all meningiomas), WHO grade 2 (atypical), and WHO grade 3 (malignant) (2). Although lower
grade tumors are considered benign, these lesions can clinically behave aggressively. In a subset of
individuals, low WHO grade meningiomas will recur despite multimodal management including
surgical resection, radiation therapy, and systemic therapy (3). Studies with long follow-up have
demonstrated recurrence rates as high as 47% after 25 years, but the role of WHO grade in
recurrence is unclear, making it challenging to select patients who would beneﬁt from adjuvant
therapies (4). Indeed, emerging data suggest that many factors not previously included in the WHO
grading schema can alter the prognosis of even benign WHO grade 1 lesions (5–10). As we will
discuss, the recently released WHO 2021 classiﬁcation marks a pivotal alteration in meningioma
grading by incorporating for the ﬁrst time key genomic alterations into the grading scheme (2, 11).
In this review, we highlight the incongruence between histologic grading and the clinical course of
meningiomas, particularly aggressively behaving lesions. First, we describe illustrative case examples of
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cm to 4.5 cm in maximal diameter. Despite radical resection
including a frontotemporal craniotomy, orbital exenteration and
radial forearm free ﬂap, the patient had multifocal tumor
recurrence and over the course of 6 months underwent SRS
twice and additional surgery for debulking and symptom relief.
She was initiated on octreotide, pembrolizumab, and everolimus
but was unable to tolerate the treatments due to skin rashes,
thrush, and constipation. Ultimately, the patient elected to proceed
with hospice care for her treatment-refractory meningioma and
passed away soon thereafter.

meningiomas with different presenting WHO grade but uniformly
aggressive clinical course. We then summarize more recently
discovered histopathological and genomic features that may
better predict meningioma aggressiveness. Finally, we describe
the current surgical, radiotherapy, and targeted drug options
available for treatment of aggressive, recurrent meningioma.

CASE EXAMPLES
While most meningiomas exhibit a benign clinical course and
favorable response to treatment with surgery or radiotherapy,
challenging cases are not uncommon. Few evidence-based
treatment algorithms have been developed to address
treatment-resistant meningiomas, in part due to the paucity of
alternatives to the traditional treatments of surgical resection and
radiotherapy (12). In this section we describe the clinical course
and treatments used to treat three meningiomas that exemplify
challenging lesions recalcitrant to treatment and that deviate
from their expected clinical course based on the 2016 WHO
classiﬁcation scheme.

WHO Grade 2
A 54-year-old man presented with deteriorating right eye vision
over the course of several years and trigeminal nerve distribution
pain, and was found to have a large cavernous sinus, middle
fossa, and infratemporal fossa mass. The patient underwent
tumor embolization followed by craniotomy and subtotal
resection, with a pathological diagnosis of WHO grade 2
meningioma with bony invasion, low MIB-1 index, no
intratumoral necrosis, and no brain invasion. The residual
tumor encasing the carotid artery was treated with fractionated
radiotherapy (54 Gy in 30 fractions).
The patient was lost to follow up but presented 4 years later
with progressive right-sided hearing loss, and his tumor was
found to have invaded the right external auditory canal, middle
cranial fossa, cavernous sinus, sphenoid sinus, and sella. The
patient underwent a craniotomy for tumor resection with
mastoidectomy and temporal bone resection, with residual
tumor encasing the petrous carotid artery deemed too highrisk to resect. One year later, the residual tumor was found to
have grown to involve the sphenoid sinus and left medial orbital
wall. He underwent embolization and tumor debulking via a
combined endonasal and transfacial approach. Eight months
later, the patient presented with persistent epistaxis requiring
embolization and was found to have extensive recurrence of his
tumor for which he underwent endoscopic endonasal debulking
once again. The pathological diagnosis after all his resections
remained WHO grade 2 meningioma, with sequencing after his
second surgery revealing only a NF2 mutation.
During subsequent observation, the patient developed right
eye blindness and left eye decline in visual acuity. He was deemed
not to be a candidate for surgical or radiation therapies and
therefore received therapy with compassionate use temsirolimus.
Unfortunately, the tumor did not respond, and the patient
developed side effects of severe hyperglycemia and eczematous
dermatitis. Two years after his last surgery, the patient developed
signiﬁcant sinonasal disease and difﬁculty eating. A gastrostomy
tube was placed for feeding and the patient underwent palliative
debulking of tumor in his sinonasal cavity before transitioning to
hospice care and expiring 3 months later.

WHO Grade 1 to WHO Grade 2
A 40-year-old woman presented with blurry vision in her left eye
and was discovered to have a left frontal mass centered above the
sphenoid wing that underwent Simpson Grade II resection and
was diagnosed as a WHO grade 1 meningioma with low Ki-67
index and no brain invasion. Within a year, the patient’s
meningioma recurred, with growth demonstrated on magnetic
resonance imaging (MRI). During her second surgical resection,
involved bone of the skull base near the orbital apex and roof was
removed (Simpson Grade I). Despite the aggressive course,
histopathological analysis once again demonstrated WHO grade
1 meningioma, with invasion of bone, and the patient underwent
adjuvant fractionated radiotherapy to the resection bed.
The patient remained symptom-free for 14 years before
experiencing worsening visual acuity, double vision with
transient left eye deviation, and pain in her left orbit. MRI
demonstrated a 2.5 cm diameter recurrence of her tumor,
invading the left orbital apex and encasing the optic nerve. She
experienced little improvement with a two-week course of
prednisone and her symptoms progressed to left eye visual loss
and proptosis over the course of a month before she underwent
Gamma Knife stereotactic radiosurgery (SRS) as salvage therapy
(15 Gy to the 50% isodose line).
The tumor initially decreased in size on serial MRI, but two
years later the patient presented with epistaxis and sinonasal
congestion, with tumor invasion of the sphenoid sinus,
pterygopalatine fossa, and masticator space. She underwent
tumor embolization followed by subtotal resection via expanded
endoscopic endonasal approach, with histopathological analysis
now consistent with WHO grade 2 meningioma with rhabdoid
features and NF2 mutation (genomic sequencing was not available
at the time of prior resections). Within 3 months post-operatively,
the size of the residual tumor increased, and by 6 months postoperatively the tumor ﬁlled the orbit and had increased from 1.8
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WHO Grade 2 to WHO Grade 3
A 49-year-old female was diagnosed with a left spheno-orbital
meningioma after presenting with left eye proptosis and
underwent tumor embolization followed by craniotomy with
gross total resection (Simpson Grade I) and adjuvant
fractionated radiotherapy with a dose of 54 Gy. Her
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meningioma taxonomy, with the addition of molecular
markers denoting a higher grade even in the absence of
traditional anaplastic features on histology (2, 11).

histopathological diagnosis at that time was WHO grade 2
meningioma with increased mitotic activity of 8 mitoses per 10
high powered ﬁelds and bony invasion. After 10 years of followup with serial MRI, she was found to have a thin area of recurrent
tumor, which was treated with SRS (20 Gy to the 50%
isodose line).
Three years later, the patient’s tumor was found to have
slightly increased in size on annual MRI scan. This was initially
managed with continued close serial observation, but one year
later the patient presented with proptosis, inferior displacement
of the left globe and diminished left eyelid function with increase
in tumor size. Subtotal surgical resection was performed, and
histopathological diagnosis remained WHO grade 2
meningioma, this time with Ki-67 index of 24.8%, and SMO
mutation detected on genomic sequencing. Her tumor increased
in size two years later, and she was initiated on octreotide and
everolimus. She tolerated octreotide well but developed
mucositis, elevated liver enzymes, anemia, and hyperlipidemia
necessitating decreased dosing of everolimus.
This therapy was continued for 2 years, until serial MRI
showed tumor progression and the patient’s left eye visual acuity
began to decline. She was enrolled in an institutional clinical trial
of proton beam therapy [20 Gy relative biological equivalents
(GyRBE) in 5 fractions], neoadjuvant avelumab (6 doses), and
surgical resection, including complete orbital exenteration, near
total tumor resection, and left thigh free ﬂap for skull base
reconstruction. Histopathological examination of the tissue was
now consistent with WHO grade 3 meningioma with foci of
rhabdoid and papillary arrangements, necrosis, brain invasion,
and 23 mitoses per high powered ﬁeld. The patient has been
followed with serial MRI showing stable residual disease one
year postoperatively.

Histopathology
The ﬁrst internationally agreed upon subtypes of meningioma
were characterized by Bailey and Cushing based on
histopathological features (17). Histopathological analysis
continues to be the basis for characterization of meningiomas,
with the current WHO grading system still retaining 15
meningioma subtypes. While previous WHO revisions further
subclassiﬁed 9 subtypes as WHO grade 1, 3 as WHO grade 2, and
3 as WHO grade 3, tumor grade is no longer coupled to subtype
in the 2021 revision (2, 11).
Each update to the WHO classiﬁcation has resulted in
dramatic shifts in the proportion of meningiomas of each
grade and have improved upon the correlation between WHO
grade and clinical course. For example, the 2000 and 2007
updates to the WHO classiﬁcation resulted in the number of
meningiomas graded as WHO grade 2 increasing from 5% to
20% (18). With the addition of brain invasion as a criterion for
WHO grade 2 meningiomas in the 2016 update, this proportion
is approximately 35%, and has increased further with the WHO
2021 classiﬁcation upgrading chordoid and clear cell
meningioma from grade 1 to grade 2 (1, 2).
More recent studies focusing on WHO grade 2 meningiomas
have uncovered histopathological features that identify a more
aggressive clinical subtype within this group of tumors, further
complicating treatment decision making for patients diagnosed
with grade 2 tumors. In 2014, Sun et al. reported that tumor
necrosis predicted radiation resistance in WHO grade 2
meningiomas that were sub-totally resected (15). Additionally,
the co-occurrence of brain invasion and high mitotic index and
the co-occurrence of brain invasion and necrosis have both been
reported to increase the risk of radiotherapy resistance and
recurrence in WHO grade 2 meningiomas (16, 19). Ultimately,
despite these improvements in correlating histopathological
features with clinical outcomes, such features remain subject to
high interobserver and sampling bias, increasing the need for
more reliable molecular markers that predict tumor behavior and
therapy resistance.

HISTOPATHOLOGY & GENETICS
Although most meningiomas are easily diagnosed with
computed tomography or magnetic resonance imaging,
histopathological analysis of tumor tissue remains the
cornerstone of tumor subtyping and grading. In recognition of
the value of molecular features in brain tumor subtyping, the
2016 World Health Organization Classiﬁcation of Tumors of the
Central Nervous System for the ﬁrst time integrated molecular
parameters in addition to histological features for classiﬁcation
of many CNS tumors (13). Unfortunately, no molecular features
were included for an integrated diagnosis of meningiomas, and,
aside from including brain invasion as a histological criterion for
WHO grade 2 meningiomas, no changes were made to
meningioma grading (13). However, certain histopathological
features, such as necrosis, have been found to predict more
aggressive treatment-resistant behavior, and there is a growing
body of evidence that speciﬁc molecular features may more
clearly delineate meningioma subtypes that better correlate
with clinical course (5–7, 14–16). The 2021 World Health
Organization Classiﬁcation of Tumors of the Central Nervous
System integrated these newer data in its recent revision of
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Genomic Analysis
The meningioma genomic landscape has been an area of
signiﬁcant investigation as early as 1994 when Ruttledge et al.
ﬁrst highlighted the prevalence of mutations in the NF2 gene,
located on chromosome 22q (20). At the time, it was well known
that loss of heterozygosity (LOH) on chromosome 22 was
present in up to 80% of meningiomas. Sequencing of the NF2
tumor suppressor gene in tumors with chromosome 22 LOH
revealed that a signiﬁcant number of tumors harbor inactivating
mutations of NF2 (20). Mutations in NF2 in the absence of
chromosome 22 LOH are rarely observed in meningiomas,
corroborating the two-hit hypothesis for the function of the
NF2 gene as a tumor suppressor in spontaneous meningiomas.
Notably, higher grade tumors more often harbor NF2
mu tations in a dd ition to large-scale chromosomal
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published (14, 30). Clark et al. identiﬁed mutations in TRAF7
(tumor necrosis factor [TNF] receptor–associated factor 7), KLF4
(Kruppel-like factor 4), AKT1 (v-akt murine thymoma viral
oncogene homolog 1), and SMO (smoothened) after sequencing
a cohort of 300 WHO grade 1 and 2 meningiomas (14).
Interestingly, these additional mutations identiﬁed three nonoverlapping groups of tumors with distinct locations: those with
chromosome 22 LOH and NF2 mutations occurring along the
convexities and posterior skull base, those with mutations in
SMO occurring in the midline anterior skull base, and those with
mutations in TRAF7, AKT1, and/or KLF4 occurring in the
sphenoid wing and ﬂoor of the middle fossa (Figure 1) (14).
Identiﬁcation of these non-NF2 driver mutations revealed that
the meningioma genomic landscape was more diverse than
previously assumed, leading to the identiﬁcation of additional
meningioma driver mutations including POLR2A, SMARCB1
germline variants (including SMARCE1), AKT3, PIK3CA,
PIK3R1, PRKAR1A, SUFU, and BAP1 (21, 24, 30–33). At the
same time, Brastianos et al. performed genomic sequencing of 17
meningiomas with further targeted sequencing on an additional
48 meningiomas, ﬁnding WHO grade 1 meningiomas have
signiﬁcantly lower rates of genomic disruptions than either
systemic tumors or WHO grade 2 or 3 meningiomas (30). In
the discovery set, some Grade 1 meningiomas were found to have
copy number loss on chromosomes 1p, 7p, 14p, and 19 with copy
number gains on chromosomes 5 and 10, while higher grade

abnormalities and overall higher mutational burden (14, 21, 22).
Further investigation of NF2 mutations in meningiomas has also
revealed that these mutations are generally associated with
convexity meningiomas rather than meningiomas of the
anterior skull base (Figure 1) (14, 23). Merlin, the protein
encoded by NF2, is as an intracellular scaffolding protein that
indirectly links F-actin, transmembrane receptors and
intracellular effectors. It has been shown to function as a
tumor suppressor by inhibiting cell growth through contact
inhibition and resultant activation of the Rac1 pathway in the
setting of high cell density. Loss of merlin function therefore
results in loss of contact inhibition of growth. NF2 mutation also
results in activation of the Hippo, Notch, phosphoinositide 3kinase (PI3K)/AKT, mammalian target of rapamycin (mTOR),
and Ras/mitogen-activated protein kinase (MAPK) pathways
with resultant increase in cell proliferation (25–29). As
described later, these insights into the molecular biology of
meningiomas have identiﬁed targets for pharmacological
agents such as tyrosine kinase inhibitors that subsequently also
decrease activation of the PI3K, mTOR, and ERK pathways.
Given that 40% of meningiomas do not have mutations in
NF2, more recent investigation has focused on identifying other
drivers of meningioma tumorigenesis using next-generation
sequencing techniques that facilitate genome-wide sequencing
in large cohorts of patients. In 2013, two seminal studies
evaluating key genetic characteristics of meningioma were

FIGURE 1 | Common intracranial locations of meningiomas highlighted in this review with associated DNA driver mutations or chromosomal loss (6, 14, 23, 24).
Locations correlated to a generalized scale ranging from less (green) to more (red) complicated to resect and manage. Meningioma locations not pictured include
clinoid, foramen magnum, cavernous sinus, suprasellar, and tentorial.
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tumors were associated with copy number loss of chromosomes
10q and 14q. Targeted gene analysis identiﬁed non-synonymous
mutations in NF2 (the most common alteration), KDM5C, SMO,
AKT1, RGPD3, and CD300C. The speciﬁc SMO mutations were
previously known oncogenic mutations in basal cell carcinoma
and desmoplastic medulloblastoma and were only found in
meningiomas without NF2 alterations. Similarly, the AKT1
mutations were oncogenic mutations previously described in
breast, colorectal, and lung cancer and were mutually exclusive
with NF2 or SMO mutations in meningioma. In validation
cohorts, the AKT1 and SMO mutations were observed in skull
base and higher grade meningiomas. Together, the ﬁndings from
Clark et al. and Brastianos et al. laid the foundation for the
inclusion of genomic alterations in the 2021 WHO classiﬁcation.
The genomic landscape speciﬁcally of WHO grade 3
meningiomas has historically been less well characterized. To
address this question, Bi et al. analyzed 134 high-grade
meningiomas. In their cohort of high grade meningiomas,
most tumors were characterized by NF2 mutations, with very
few tumors having mutations in TRAF7, KLF4, AKT1 and SMO,
suggesting that high grade meningiomas have few targetable
genetic mutations. Associations were also reported between
AKTI/PIK3CA mutations and meningothelial subtype, NF2
mutations and ﬁbroblastic subtype, and TRAF7/KLF4
mutations and secretory subtype. Bi et al. also found that high
grade lesions were characterized by increased copy number
alterations, and, interestingly, low grade lesions that progressed
to high grade meningiomas exhibited patterns of genomic
disruption similar to high grade meningiomas and have been
associated with activating TERT promoter mutations (21, 34).
Presence of a TERT promoter mutation is further associated with
progression and poor survival (35, 36). This observation
combined with other groups demonstrating a strong
association between homozygous deletion of CDKN2A/B or
BAP1 mutations and aggressive clinical outcome led to a
signiﬁcant revision in the 2021 WHO criteria (2, 37–39).
While the 2021 classiﬁcation recommends considering
sequencing, it is not required for diagnosis (2). Nonetheless,
the current criteria now integrates driver mutations such as NF2,

AKT1, SMO, and PIK3CA for conventional, TRAF7 and KLF4 for
secretory, SMARCE1 for clear cell, and BAP1 for rhabdoid
subtypes (2, 11). Furthermore, a meningioma harboring either
a TERT promotor mutation or homozygous deletion of
CDKN2A/B is classiﬁed as a grade 3 anaplastic tumor,
regardless of histologic grade (11).

Expression Proﬁle and Epigenomic Analysis
Given that WHO grade and DNA mutations do not optimally
predict the clinical behavior of meningiomas, recent studies have
used several molecular analysis techniques to create classiﬁcation
schemes more aligned with meningioma clinical course
(Table 1). Many groups have hypothesized that chromatin
structure and gene expression proﬁles, governed largely by
DNA methylation, might be more useful in this regard (40–
42). For example, the loss of H3K27 trimethyl (H3K27me3)
identiﬁed by immunohistochemistry has been corroborated as a
marker of poor survival and shorter time to recurrence,
speciﬁcally in Grade 2 meningioma (43, 44).
In 2017 Sahm et al. performed genome-wide methylation
analysis of 497 meningiomas across all WHO grades and 309
extra-axial tumors that mimic meningiomas histologically (5).
Unsupervised clustering not only segregated meningiomas from
the other tumors but also identiﬁed six clinically relevant
methylation classes of meningiomas. Three classes clustered
together and were deﬁned as methylation class benign 1 to 3
(MC ben-1 to MC ben-3) based on having a more benign clinical
course. Two classes, deﬁned as methylation class intermediate A
and B (MC int-A and MC int-B) had an intermediate
progression-free survival, and the ﬁnal class, methylation class
malignant (MC mal), had a markedly poor progression-free
survival. Notably, while WHO grade 1 meningiomas were
enriched in the benign methylation classes and WHO grade 3
meningiomas in the malignant methylation class, WHO grade 2
lesions, which often have a heterogenous clinical course, were
scattered across all but one of the methylation classes.
Furthermore, NF2 mutations were found in at least 30% of all
methylation classes except for MC ben-2. Consistent with
ﬁndings from genomic sequencing studies, non-NF2 and NF2

TABLE 1 | A comparative representation of studies describing molecular reclassiﬁcation of meningiomas.
Bayley et al, 2022 (10)
MenG A
TRAF7
AKT1
KLF4
SMO
POLR2A
SMARCB1
Chr22q Loss
NF2
Chr1p Loss
TERT

MenG B

MenG C

Nassiri et al, 2021 (7)
Group 1

Group 2

Group 3

N/A

N/A

N/A

Maas et al, 2021 (8)
Group 4

Subtype 1 (Low)

Subtype 2 (Int)

Subtype 3 (High)

N/A
N/A
N/A

N/A
N/A
N/A

N/A
N/A
N/A

N/A

Within each classiﬁcation scheme, meningioma subgroups are ordered from left to right based on increasingly worse progression free survival. Genetic mutations and chromosomal losses
were compared across each subgroup with black shading indicating predominant mutation/loss in that group, empty cell indicating that the mutation/loss was tested for but was not
present or signiﬁcantly less predominant in that group, and N/A indicating that the mutation/loss was not tested for or not reported in that study.
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TABLE 2 | Comparison of contemporary aggressive meningioma prognostication.

mutations occurred almost mutually exclusively, with non-NF2
mutations being enriched in MC ben-2, while NF2 mutations
were rare in this group (5). Taken together, these ﬁndings suggest
that methylation classes are superior to WHO grade for
predicting clinical behavior, especially in the case of WHO
grade 2 tumors, and that although NF2 mutational status may
not be an entirely speciﬁc predictor for clinical behavior, nonNF2 driver mutations may be useful in identifying meningiomas
with a more benign clinical course.
In 2019 Patel et al. reported their classiﬁcation scheme based
on combined bulk RNA sequencing and whole exome
sequencing analysis of 160 meningiomas (6). They too
reported 3 molecular subgroups, named type A, B, and C that
predicted recurrence more reliably than the WHO grading
schema. Interestingly, they found that more than half of the
tumors in their most aggressive subgroup (type C) were
predicted to be benign by WHO grading criteria. Like prior
studies, the least aggressive tumors (type A) were found to have
no notable copy number alterations while the most aggressive
tumors (type C) were found to have the greatest rates of
chromosome 22q and 1p losses. Importantly, gene set
enrichment analysis of type B and type C tumors revealed loss
of PRC2 complex function in type B and loss of DREAM
complex function in type C tumors, insights which might
guide targeted treatment strategies in the future (6).
More recently, Nassiri et al. performed an integrative analysis
of 121 meningiomas with methylation array, bulk RNA
sequencing, and whole exome sequencing analysis to develop
an integrated classiﬁcation system to better predict outcome than
the WHO grading system (7). They identiﬁed 4 molecular
subgroups of meningioma, MG1-4, and designated each
subgroup based on pathway analysis of enriched genes:
immunogenic (MG1), benign NF2 wild-type (MG2),
hypermetabolic (MG3), and proliferative (MG4). Interestingly,
mapping drugs to target-enriched genes identiﬁed possible drug
candidates for speciﬁc meningioma subtypes. For example, the
histone deacetylase inhibitor vorinostat, which mapped to the
MG4 subtype, was found to speciﬁcally decrease the viability of
the MG4 meningioma cell line in vitro and decrease the size of
MG4 xenografts in vivo, highlighting the value of molecular
analysis of meningiomas both in classiﬁcation and in
development of novel therapies (7).
Maas et al. and Bayley et al. have similarly created
meningioma classiﬁcation systems that integrate a combination
of methylation array data, copy number alterations, DNA
mutations, and histopathological ﬁndings to better stratify
patients (Table 2) (8, 10). Importantly, Maas et al.
demonstrated that copy number alteration data can readily be
inferred from methylation arrays, thus streamlining the
molecular diagnostic workup of meningiomas, although they
also provide alternative assays (targeted gene analysis or FISH)
for stratiﬁcation depending on resource availability (8). Bayley
et al. combined DNA methylation, RNA-seq, and cytogenic
proﬁling on WHO grade 1 and 2 meningiomas yielding three
subgroups of meningiomas, two malignant and one benign.
Notably chromosome 1p loss was strongly correlated with
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Driver
Classiﬁcation
(9)

Maas
Classiﬁcation
(8)

RTOG
0539
(45)

WHO
2021
(2)

CNV
1p
3p
4p/q
6p/q
10p/q
14q
18p/q
19p/q
CDKN2A/B
Mitoses
4 to 19
>20
EOR
GTR
STR
Tumor Volume
0-25 cc
>25cc
Recurrence
rimary
Recurrent
WHO Grade
1
2
3
Methylation
Proﬁle
Ben
Int
Mal
Genetic
Alterations
SMARCE1
BAP1
KLF/TRAF7
TERT
Histology
Key factors of four contemporary meningioma grading schemata, including genetic and
epigenetic alterations, histologic characteristics, and clinical characteristics, are
compared. Within each classiﬁcation scheme, black shading indicates use of the factor
in the prognostication score.

malignant tumors (10). These integrated models yielded a
greater accuracy for prognosis compared to RNA-sequencing
and cytogenic proﬁling or DNA methylation alone.
Meanwhile, Driver at al. incorporated 15 targeted, high-risk
molecular alterations (13 chromosomal alterations and loss of
CDKN2A/B) with histologic (presence of frequent mitoses) and
clinical (extent of resection, tumor volume, and recurrence
status) factors to stratify meningioma. This classiﬁcation
system highlights the importance of incorporating CDKN2A
mutations, with their classiﬁcation system resulting in
reclassiﬁcation of 32% of tumors into either a higher or lower
risk integrated grade compared to their WHO grade (9). Taken
together, these recent studies suggest that a combination of
molecular and histopathological properties need to be
considered for accurate stratiﬁcation of meningiomas. Indeed,
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dependent on the consistency of the tumor, its involvement with
surrounding structures, and tumor shape (57–59).
The location of a meningioma greatly affects a surgeon’s
ability to achieve complete resection, with increasing
complexity, for example, for convexity, parasagittal, sphenoid
wing, cerebellopontine, and petroclival meningiomas (Figure 1).
Convexity meningiomas typically present to the surface of the
brain, placing fewer neurovascular structures at risk during
dissection. Thus, given a generally low surgical risk, complete
resection represents the standard of care for both initial surgical
resection and for recurrence of aggressive convexity
meningiomas. Similarly, falcine meningiomas that by deﬁnition
arise from the falx but do not involve the superior sagittal sinus
can generally be completely resected, frequently by an
interhemispheric approach (60). In contrast, parasagittal
meningiomas can abut or even invade the superior sagittal
sinus, limiting a surgeon’s ability to achieve a gross total
resection without incurring the risks associated with sinus
thrombosis and venous infarction. Such cases require close
monitoring of residual tumor for progression, with
consideration for adjuvant therapy for clinically aggressive
lesions (61, 62).
Clinoidal, sphenoid wing, and spheno-orbital meningiomas
can also be more technically challenging, particularly with
increasing meningioma size and more medial location along
the sphenoid wing, given proximity to the optic nerve, internal
carotid artery and its branches, and the cavernous sinus (47, 63).
Such tumors may be amenable to frontotemporal craniotomy, an
eyebrow approach, or in some cases a TONES (TransOrbital
NeuroEndoscopic Surgery) approach to remove the lesion.
Additional bony removal to improve resection of larger, more
invasive lesions might include anterior clinoidectomy, optic
nerve decompression, orbitozygomatic osteotomy, and removal
of hyperostotic, tumor-inﬁltrated bone. Complete resection of
aggressive, recurrent lesions may be limited by encasement of
critical structures such as the internal carotid artery or
inﬁltration into the cavernous sinus. Fortunately, adjuvant
treatment of such lesions can yield control rates as high as
70%, although more aggressive approaches such as carotid
bypass or cavernous sinus entry to remove additional tumor
should be considered in certain cases (64).
Meningiomas localized within the cerebellopontine angle are
associated with further operative risk due to proximity to the
brainstem, cranial nerves, and high-ﬂow vasculature. The
operative corridor to the cerebellopontine angle depends on
size of the meningioma and relationship to the cranial nerves.
Possible approaches include the retrosigmoid craniotomy and
posterior petrosal approach, among others. A case study of 34
patients with cerebellopontine angle meningiomas demonstrated
a 35.3% rate of cranial nerve deﬁcits postoperatively, particularly
when tumor is greater than 3 cm or extends into the jugular
foramen (65). Given the critical structures surrounding the
cerebellopontine angle, complete resection might not be
possible, particularly with signiﬁcant extension into the jugular
foramen or with brainstem invasion. Tentorial meningiomas,
which represent 3-6% of intracranial meningiomas, represent a

use of machine learning techniques may allow for inclusion of
even more information, such as MRI characteristics of tumors,
into intergrated grading schema that more accurately stratify
meningiomas (46).

CLINICAL MANAGEMENT
Active meningioma management includes surgical resection,
radiation therapy, and pharmacological options (47, 48).
Observation is another option, generally reserved for small,
asymptomatic, or incidental lesions and for patients that are
deemed poor candidates for other therapeutic options (49).
These patients are typically monitored with serial MRI scans.
Tumor growth or symptom progression can indicate that
observation has failed, and additional treatment may be
necessary. In a retrospective study of 244 patients, Oya et al.
demonstrated tumor diameter at diagnosis greater than 25 mm,
MRI T2 signal hyperintensity, absence of calciﬁcation, and
edema predicted tumor growth (50). Additional retrospective
studies validated these ﬁndings and demonstrated tumors > 40
mm at diagnosis and with initial volumetric growth rates of 20%
per year are highly likely to progress (51–53). Presence of focal or
diffuse calciﬁcation is perhaps one of the strongest preoperative
radiographic predictors that a meningioma is unlikely to recur,
demonstrating 0% recurrence rate in one retrospective study of
101 patients, compared to nearly 21% recurrence rates in
meningiomas without calciﬁcation observed (54). While many
patients with meningioma under observation are asymptomatic,
temporarily mitigating mild symptoms is possible with low-dose
steroids to alleviate edema and antiepileptic medications for
patients that present with seizure.

Surgery
With symptomatic lesions, tumor progression, or mitigating
factors such as patient preference, an active management
strategy is often required. For patients without signiﬁcant
medical comorbidities, surgical resection is considered ﬁrst-line
treatment and can often be curative. Selecting a surgical
approach is a nuanced decision based on the speciﬁc
meningioma location that must balance surgical risk with a
need to achieve complete resection as described by the
Simpson Grading Scale, deﬁned by removal of the tumor with
tumor-inﬁltrated dura, bone, and venous sinuses (47, 55, 56).
Fundamentals of meningioma surgery are based on the general
principle that they are extra-axial lesions, and bone must be
removed to permit sufﬁcient exposure of the lesion and minimize
injury to surrounding neurovascular structures. The
meningioma is ﬁrst devascularized at its base to minimize
bleeding, the core is debulked, and the now malleable capsule
dissected from neurovascular structures. In select cases,
preoperative embolization may aid devascularization. Tumor
removal can be signiﬁcantly more complicated for
meningiomas with close involvement of cranial nerves or a
venous sinus. Gross total resection of a meningioma is highly
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these lesions and is considered standard of care even after
complete resection for aggressive or grade 3 lesions (76).
Small (< 3 cm) WHO grade 1 meningioma may be treated
with single- or multi-session radiosurgery, though this is not
commonly used in higher-grade meningiomas except in cases of
repeat irradiation (77–79). For larger meningiomas of high grade
or with aggressive features, fractionated radiotherapy alone or in
addition to surgery is often recommended, typically 54 Gy for
grade 1 and 59.4 – 60 Gy for grade 2-3 lesions. Fractionated
radiosurgery following subtotal resection in patients with WHO
grade 1 meningiomas demonstrated 5-year progression free
survival (PFS) of 91%, compared to 52% of patients that had
subtotal resection alone (80). Similar comparisons in WHO
grade 2 and 3 patients demonstrated signiﬁcant increase in
median PFS from 37 months to 64 months with addition of
adjuvant fractionated radiotherapy, although this beneﬁt is likely
reduced in aggressive and recurrent meningiomas, which may be
identiﬁed based on the presence of intratumoral necrosis or brain
invasion, as previously described (81–83).
The efﬁcacy of radiation therapy is highly relevant for surgically
complex tumors where gross total resection is not possible. Large
retrospective analyses of symptomatic patients with petroclival,
cavernous sinus, and cerebellopontine meningiomas reveal tumor
control by radiation therapy in greater than 90% of cases with
signiﬁcant improvement in cranial nerve function (46.5%),
particularly in petroclival and cavernous sinus meningiomas (84,
85). These ﬁndings were replicated in a series of retrospective
analyses meta-analyses speciﬁcally looking at patients with
cavernous sinus meningiomas treated with fractionated
radiotherapy, demonstrating a local control rate of approximately
90% at 10 years with cranial nerve deﬁcit improvement in 26-45% of
patients and a 10% rate of new cranial nerve dysfunction (86–90).
Clinical trials further investigating the application of fractionated
radiotherapy in the treatment of meningioma are ongoing with
encouraging results. For example, preliminary results from RTOG
0539, a phase II clinical trial in which patients were assigned
radiation treatment protocols based on grouping into low,
intermediate and high-risk groups by extent of resection, WHO
grade, and recurrence status indicate a PFS of 94% for intermediateand 59% for high-risk meningiomas treated with adjuvant
fractionated radiotherapy (45, 91). A lingering question is the
need for adjuvant radiation therapy following gross total resection
of an intermediate grade meningioma, and may be answered by an
ongoing phase 3 clinical trial (NCT03180268). Of note, inclusion in
this trial requires pathologic diagnosis of WHO grade 2
meningioma according to the 2016 criteria, and therefore may
not entirely assess the genetic and epigenetic subclassiﬁcations
described in recent years and incorporated into the WHO
2021 classiﬁcation.

similarly technically complex subset of meningiomas. Depending
on the location, surgical approaches include the subtemporal,
suboccipital, or supracerebellar infratentorial approaches (66).
Petroclival meningiomas, originating at the upper clival dura
medial to the trigeminal nerve, represent one of the most
technically challenging meningiomas to treat surgically, given
their ventral location in relation to the brainstem and
involvement of multiple cranial nerves, with high rates of
surgical morbidity (67). Variants such as the sphenopetroclival
meningiomas can further extend into the middle fossa and
invade the cavernous sinus. Complete resection of these
tumors is often not possible and a combination of approaches,
such as retrosigmoid, presigmoid, subtemporal transtentorial
transpetrosal, and pretemporal transcavernous approaches,
may be needed. Recent advances in endoscopy have opened a
new avenue for resection, with the endonasal corridor providing
direct access to the ventrally located meningioma via the clivus,
reducing retraction on the brainstem or cranial nerves and
greatly improving extent of resection (68–71).
Similarly, meningiomas of the anterior midline skull base (e.g.
parasellar or olfactory groove) may be accessed by either
expanded endoscopic approach or open craniotomy, often
through frontotemporal or subfrontal approaches (72, 73). The
expanded endoscopic approach is an increasingly viable option
providing early visibility of the anterior fossa with minimal brain
retraction and provides an opportunity for early decompression
of the optic canal to reduce the risk of optic nerve injury. While
such approaches are associated with increased risk of anosmia
and cerebrospinal ﬂuid (CSF) leak, advent of the vascularized
nasoseptal ﬂap has vastly reduced the rate of CSF leak.
Other locations of intracranial meningiomas are described in
the literature but are less commonly observed and are therefore
not comprehensively discussed in this review. For example,
intraventricular meningiomas, which represent less than 3% of
intracranial meningiomas, account for up to 15% of adult
intraventricular neoplasms and can present with either mass
effect or obstructive hydrocephalus; the most common left
trigonal location is often approached through a superior
parietal lobule or occipital avenues (74). Surgical approach for
each subset of intracranial meningioma not discussed must be
tailored to maximize resection while minimizing risk of injury to
vasculature, cranial nerves, and brain parenchyma.

Radiation Therapy
In elderly or medically ill patients, for surgically inaccessible
tumors, or as an adjunct to open surgery, stereotactic
radiosurgery is a treatment option that is particularly effective
for smaller lesions, with 5 year progression-free survival rates
ranging from 86-100% (18). Although surgery is widely
considered ﬁrst-line treatment for symptomatic or progressive
meningiomas in a healthy patient population, complex tumors
that are closely involved with critical neurovascular structures
may not permit complete resection. Particularly for aggressive
meningiomas, residual tumor, such as that left within the
superior sagittal sinus, cavernous sinus, or encasing cranial
nerves, is associated with a 5-year recurrence rate greater than
60% (75). Therefore, adjuvant therapy must be considered for
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Systemic Therapy
Medical management for meningioma is typically reserved as
salvage therapy in aggressive, recurrent cases without surgical or
radiotherapeutic options. Unfortunately, there is a lack of largescale positive controlled trials on which to base recommendations,
highlighting the importance of ongoing clinical trials. Instead,
recommendations are based on small-scale studies evaluating a
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and a recommendation level C from EANO, though caution is
warranted given potential bleeding risk (48, 102).
Meningiomas demonstrate the highest incidence of
somatostatin receptor expression of all human tumors,
garnering interest in leveraging somatostatin analogues for
treatment of refractory lesions (105). The somatostatin
receptor subtype overexpressed in 70% of meningiomas, SST2A,
strongly binds the widely available analog, octreotide (106). In
vitro, octreotide inhibits meningioma cell proliferation, but does
not induce cell death, particularly in cells expressing high levels
of the SST2A receptor (107). A prospective pilot study that
treated 16 patients with recurrent meningioma with octreotide
yielded a radiographic response in 31% of patients, with an
additional one-third of patients exhibiting stable disease at 6
months, with minimal associated drug toxicity (108). While this
beneﬁt was not observed in a prospective, phase II study of 8
patients with recurrent, treatment-resistant meningioma or
hemangiopericytoma, a large retrospective analysis of 43 (only
11 of whom were grade 2 or 3) patients with refractory
meningioma treated with octreotide demonstrated improved
progression-free survival particularly in skull base lesions (109,
110). Given the possible clinical beneﬁt of octreotide with
minimal toxicity, the CNS NCCN guideline classiﬁes it as a
level 2B drug for patients with recurrent meningioma.
Disruptions in the mTOR pathway are well documented in
high grade meningiomas, with mTOR inhibition associated with
decreased proliferation in vitro (107, 111). This has resulted in
several studies examining combination therapy of everolimus, a
small molecule mTOR kinase inhibitor, to other systemic
treatments for recurrent meningiomas, including octreotide
and bevacizumab (104, 112, 113). The phase II CEVOREM
trial of 20 patients reported a median PFS of 6.6 months of the
combination of octreotide and everolimus, while a median PFS of
12.1 months was reported by Cardona and colleagues for their
retrospective study of 14 patients treated with everolimus,
octreotide, and sunitinib (104). Finally, the combination of
everolimus and bevacizumab has also been promising, with a
median PFS of 22 months in grade 2 and 3 meningiomas (112).
Though it remains unclear if there was additional beneﬁt from
combinatorial therapy, the combination of everolimus and
bevacizumab carries a level 2B recommendation from the
NCCN, with multiple mTOR pathway-targeting drugs being
actively investigated.
Immunotherapeutic agents have demonstrated mixed efﬁcacy
to date in meningioma. Recombinant interferon-a is one such
agent that demonstrated in vitro inhibition of meningioma cells
(114). A prospective study of 35 patients with treatmentrefractory WHO grade 1 meningiomas treated with interferona had promising results, yielding a median progression-free
survival of 7 months. Although no radiographic response was
noted in these patients, the study did demonstrate a modest
control rate compared to historical controls. Unfortunately,
interferon-a had limited efﬁcacy for aggressive, high-grade
tumors; a retrospective study of 35 patients receiving
interferon-a demonstrated just 17% PFS at 6 months and no
evident radiographic response (115). Similarly, immune

wide variety of drug classes. These include recombinant antibodies
(such as the anti-angiogenesis drug class), small peptides (e.g.
somatostatin analogues), and a range of small molecule targeted
therapies (48, 92–94). Traditional cytotoxic agents have had
limited success (95, 96).
The NCCN guidelines (version 2.2021) for the treatment of
recurrent meningioma has four category 2 recommended
treatments: bevacizumab (2A), sunitinib (2B), a combination of
bevacizumab with everolimus (2B), and somatostatin analogue
(2B, “useful in certain circumstances”). Here we ﬁrst review the
NCCN recommendations for different salvage therapies before
discussing additional treatment options.
Therapies targeting angiogenesis predominately affect the
Vascular Endothelial Growth Factor (VEGF) pathway. A tenfold elevation of VEGF levels have been reported in high grade as
compared to low grade meningiomas (97). Vasogenic edema
associated with meningiomas likewise is correlated with tumor
VEGF expression levels, suggesting promise for therapies
targeting angiogenesis in certain meningiomas (98). Drugs
directly and indirectly targeting this pathway include
bevacizumab (targeted inhibition of VEGF-A), vatalanib
(VEGF/PDGF receptor inhibition), and sunitinib (non-speciﬁc
tyrosine kinase inhibitor) (48, 95). Of these agents, bevacizumab
is the best studied, with reported median PFS ranging from 6 to
15 months across several retrospective and prospective phase 2
studies (94, 99–101). As summarized by Graillon et al. in their
recent review, the majority of these studies are small, enrolling
between 8 and 38 patients with grade 2 or 3 meningiomas (94,
100). This combined with heterogeneity of study populations
between studies warrants caution when interpreting consensus
guidelines. When compared to a range of systemic agents as part
of a retrospective study, Furtner et al. also noted those receiving
bevacizumab demonstrated an 80% reduction in tumor diameter
and 107% reduction in peritumoral edema (95). While
promising, a prospective study by Furuse et al. suggests this
may be due to bevacizumab treating post-radiation
intraparenchymal radiation necrosis rather than targeting
viable tumor (100). Bevacizumab is the only NCCN 2A
recommended systemic treatment for recurrent meningioma.
Likewise, the European Association of Neuro-Oncology
(EANO) recommends bevacizumab in cases without alternative
local treatment options, with a European evidence level of III
(48, 102).
One prospective phase 2 and one retrospective study have
examined sunitinib in recurrent meningiomas, enrolling 36 and
11 patients respectively (103, 104). Kaley et al. reported
expression of VEGF-R2 in high grade meningiomas was
associated with a median PFS of 1.4 months compared to 6.4
in patients who lacked its expression. Unfortunately,
hemorrhages were observed in 4 of 36 patients on the study
(two grade 3, one grade 4, and one grade 5), with additional
thrombotic microangiopathy noted in 2 patients (103). More
recently, Cardona et al. reported a median PFS of 9.1 months in
eleven patients treated with sunitinib, notably without reports of
CNS hemorrhage or angiopathy their smaller retrospective
cohort (104). Sunitinib carries a NCCN 2B recommendation
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(127). Tumors with AKT1, PIK3CA or PTEN mutations are
treated with capivasertib, an AKT kinase inhibitor, and those
with CDK4, CDK6, CDKN2A, CCND1, CCND2, CCND3, and
CCNE1 treated with abemaciclib, a CDK inhibitor. As additional
molecular drivers of meningioma pathophysiology are identiﬁed,
additional targeted therapies will undoubtedly be revealed for
recurrent lesions.

checkpoint inhibition by the programmed death-1 ligand (PDL1) pathway (known to be upregulated in high-grade
meningiomas) has failed to demonstrate signiﬁcant response to
date, with a recent phase 2 study of nivolumab monotherapy in
25 patients failing to demonstrate improved progression free
survival (116). Despite initial setbacks, several immunotherapies
remain under active evaluation including nivolumab,
pembrolizumab, and avelumab.
Also under investigation for the treatment of meningioma are
tyrosine kinase inhibitors. Interest in this category arose from the
ﬁnding of activated PI3K and MAPK signaling pathways in
aggressive meningiomas (117–119). Two such tyrosine kinase
inhibitors with proven tolerability and efﬁcacy in other tumors,
sorafenib and regorafenib, were shown to impair cell viability
and increase apoptosis in vitro with meningioma cells and to
improve survival in an in vivo murine xenograft (120). A 2014
phase II clinical study treated 25 patients with aggressive
meningioma with an oral tyrosine kinase inhibitor of VEGFR,
vatalanib, with 6 month PFS of 54% (121). There are multiple
additional tyrosine kinase inhibitors under investigation,
targeting various receptor tyrosine kinase such as EGFR,
PDGF, and FGFR with results pending (122–125).
As described above, molecular analysis of meningiomas has
identiﬁed numerous driver mutations in genes that can be targeted
with small molecular inhibitors or other therapeutic strategies. A
promising phase 2 clinical trial, NCT02523014, led by Brastianos
et al. is currently ongoing with 4 arms (2 closed, 2 ongoing)
designed to tailor therapy to the speciﬁc molecular alterations
identiﬁed in patients’ meningiomas (126). Meningiomas with
SMO or PTCH1 mutations were treated with vismodegib, an
FDA-approved Hedgehog signaling pathway inhibitor. Those
with NF2 mutations received a FAK inhibitor, thought to act as
a synthetic lethal with NF2 loss-of-function, with results from this
arm reported as showing improved PFS at 6 months (33%)
compared to historical controls with minimal adverse effects

CONCLUSIONS
Although often considered a benign entity, many intracranial
meningiomas are anything but, requiring potentially morbid
surgical resections and radiation treatments with few viable
systemic therapy alternatives. WHO grading predicts
aggressiveness of meningiomas relatively well, but as
demonstrated in the descriptive case examples, is not perfect,
particularly in the broad classes of grade 2 lesions. Recent progress
in characterization of the genetic and epigenetic landscape of these
lesions may signiﬁcantly improve our ability to better delineate
aggressive tumors. Such tumors may be well-served with
immediate postoperative adjuvant therapy or closer monitoring.
Finally, improved molecular understanding has permitted targeted
therapies including antiangiogenic agents, tyrosine kinase
inhibitors, somatostatin inhibitors, and genetically targeted small
molecular inhibitors with highly anticipated results from ongoing
clinical trials.
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et al. Systemic Management of Malignant Meningiomas: A Comparative Survival
and Molecular Marker Analysis Between Octreotide in Combination With
Everolimus and Sunitinib. PloS One (2019) 14:e0217340. doi: 10.1371/
journal.pone.0217340
105. Lamberts SW, Krenning EP, Reubi JC. The Role of Somatostatin and its
Analogs in the Diagnosis and Treatment of Tumors. Endocr Rev (1991)
12:450–82. doi: 10.1210/edrv-12-4-450
106. Schulz S, Pauli SU, Schulz S, Handel M, Dietzmann K, Firsching R, et al.
Immunohistochemical Determination of Five Somatostatin Receptors in
Meningioma Reveals Frequent Overexpression of Somatostatin Receptor
Subtype Sst2a. Clin Cancer Res (2000) 6:1865–74.
107. Graillon T, Romano D, Deﬁlles C, Saveanu A, Mohamed A, FigarellaBranger D, et al. Octreotide Therapy in Meningiomas: In Vitro Study,
Clinical Correlation, and Literature Review. J Neurosurg (2017) 127:660–9.
doi: 10.3171/2016.8.JNS16995
108. Chamberlain MC, Glantz MJ, Fadul CE. Recurrent Meningioma: Salvage
Therapy With Long-Acting Somatostatin Analogue. Neurology (2007)
69:969–73. doi: 10.1212/01.wnl.0000271382.62776.b7
109. Johnson DR, Kimmel DW, Burch PA, Cascino TL, Giannini C, Wu W, et al.
Phase II Study of Subcutaneous Octreotide in Adults With Recurrent or

Frontiers in Oncology | www.frontiersin.org

110.

111.

112.

113.

114.

115.

116.

117.

118.

119.

120.

121.

122.

123.
124.

125.

126.

127.

13

Progressive Meningioma and Meningeal Hemangiopericytoma. Neuro Oncol
(2011) 13:530–5. doi: 10.1093/neuonc/nor044
Hrachova M, Nguyen ENT, Fu BD, Dandekar MJ, Kong XT, Cadena G, et al.
A Retrospective Interventional Cohort Study to Assess the Safety and
Efﬁcacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory
Meningiomas. Front Neurol (2020) 11:373. doi: 10.3389/fneur.2020.00373
Graillon T, Deﬁlles C, Mohamed A, Lisbonis C, Germanetti AL, Chinot O,
et al. Combined Treatment by Octreotide and Everolimus: Octreotide
Enhances Inhibitory Effect of Everolimus in Aggressive Meningiomas.
J Neuro-oncol (2015) 124:33–43. doi: 10.1007/s11060-015-1812-3
Shih KC, Chowdhary S, Rosenblatt P, Weir AB 3rd, Shepard GC, Williams
JT, et al. A Phase II Trial of Bevacizumab and Everolimus as Treatment for
Patients With Refractory, Progressive Intracranial Meningioma. J NeuroOncol (2016) 129:281–8. doi: 10.1007/s11060-016-2172-3
Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyriere H, et al.
Everolimus and Octreotide for Patients With Recurrent Meningioma:
Results From the Phase II CEVOREM Trial. Clin Cancer Res (2020)
26:552–7. doi: 10.1158/1078-0432.CCR-19-2109
Koper JW, Zwarthoff EC, Hagemeijer A, Braakman R, Avezaat CJJ, Bergstrom M,
et al. Inhibition of the Growth of Cultured Human Meningioma Cells by
Recombinant Interferon-Alpha. Eur J Cancer (1991) 27:416–9. doi: 10.1016/02775379(91)90375-n
Chamberlain MC. IFN-Alpha for Recurrent Surgery- and RadiationRefractory High-Grade Meningioma: A Retrospective Case Series. CNS
Oncol (2013) 2:227–35. doi: 10.2217/cns.13.17
Bi WL, Nayak L, Meredith DM, Driver J, Du Z, Hoffman S, et al. Activity of
PD-1 Blockade With Nivolumab Among Patients With Recurrent Atypical/
Anaplastic Meningioma: Phase II Trial Results. Neuro Oncol (2021) 24
(1):101–13. doi: 10.1093/neuonc/noab118
Johnson M, Toms S. Mitogenic Signal Transduction Pathways in
Meningiomas: Novel Targets for Meningioma Chemotherapy?
J Neuropathol Exp Neurol (2005) 64:1029–36. doi: 10.1097/
01.jnen.0000189834.63951.81
Mawrin C, Sasse T, Kirches E, Kropf S, Schneider T, Grimm C, et al. Different
Activation of Mitogen-Activated Protein Kinase and Akt Signaling is
Associated With Aggressive Phenotype of Human Meningiomas. Clin
Cancer Res (2005) 11:4074–82. doi: 10.1158/1078-0432.CCR-04-2550
Johnson MD, Reeder JE, O'Connell M. MKP-3 Regulates PDGF-BB Effects
and MAPK Activation in Meningioma Cells. J Clin Neurosci (2015) 22:752–
7. doi: 10.1016/j.jocn.2014.10.030
Tuchen M, Wilisch-Neumann A, Daniel EA, Baldauf L, Pachow D, Scholz J,
et al. Receptor Tyrosine Kinase Inhibition by Regorafenib/Sorafenib Inhibits
Growth and Invasion of Meningioma Cells. Eur J Cancer (2017) 73:9–21.
doi: 10.1016/j.ejca.2016.12.004
Raizer JJ, Grimm SA, Rademaker A, Chandler JP, Muro K, Helenowski I,
et al. A Phase II Trial of PTK787/ZK 222584 in Recurrent or Progressive
Radiation and Surgery Refractory Meningiomas. J Neuro-Oncol (2014)
117:93–101. doi: 10.1007/s11060-014-1358-9
Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, et al.
Phase II Trials of Erlotinib or Geﬁtinib in Patients With Recurrent Meningioma.
J Neuro-oncol (2010) 96:211–7. doi: 10.1007/s11060-009-9948-7
Ragel BT, Jensen RL. Aberrant Signaling Pathways in Meningiomas. J Neurooncol (2010) 99:315–24. doi: 10.1007/s11060-010-0381-8
Johnson MD, O'Connell MJ, Pilcher W, Reeder JE. Fibroblast Growth Factor
Receptor-3 Expression in Meningiomas With Stimulation of Proliferation by
the Phosphoinositide 3 Kinase-Akt Pathway. J Neurosurg (2010) 112:934–9.
doi: 10.3171/2009.7.JNS09726
Choy W, Kim W, Nagasawa D, Stramotas S, Yew A, Gopen Q, et al. The
Molecular Genetics and Tumor Pathogenesis of Meningiomas and the
Future Directions of Meningioma Treatments. Neurosurg Focus (2011) 30:
E6. doi: 10.3171/2011.2.FOCUS1116
Ippen FM, Colman H, van den Bent MJ, Brastianos PK. Precision Medicine
for Primary Central Nervous System Tumors: Are We There Yet? Am Soc
Clin Oncol Educ Book (2018) 38:158–67. doi: 10.1200/EDBK_199247
Brastianos PK, Twohy E, Gerstner ER, Kaufmann TJ, Iafrate AJ, Jeyapalan
SA, et al. Alliance A071401: Phase II Trial of FAK Inhibition in Meningiomas
With Somatic NF2 Mutations. J Clin Oncol (2020) 38:2502–2. doi: 10.1200/
JCO.2020.38.15_suppl.2502

March 2022 | Volume 12 | Article 851758

Patel et al.

Aggressive Meningioma - Identiﬁcation and Treatment

Conﬂict of Interest: AK is a consultant for Monteris Medical and has received
research grants from Monteris Medical for a mouse laser therapy study as well as
from Stryker and Collagen Matrix for clinical outcomes studies about a dural
substitute, which have no direct relation to this study.

the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Copyright © 2022 Patel, Desai, Pugazenthi, Butt, Huang and Kim. This is an openaccess article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.

The remaining authors declare that the research was conducted in the absence of
any commercial or ﬁnancial relationships that could be construed as a potential
conﬂict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their afﬁliated organizations, or those of

Frontiers in Oncology | www.frontiersin.org

14

March 2022 | Volume 12 | Article 851758

